EUVIMEDEUVIMED entdecken
Crossref

Predictors of survival outcomes in patients with neuroendocrine neoplasms: a real-world retrospective study

Marta Laganà, Fabio Gallo, Maddalena Salvetti, Davide Smussi, Andrea Esposito, Giorgia Carola, Matteo Carpani, Filippo Morocutti, Deborah Cosentini, Rebecca Pedersini, Salvatore Grisanti, Alfredo Berruti und 1 weitere

Endocrine-Related Cancer · 2025

DOI: 10.1530/erc-25-0243 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Endocrine-Related Cancer, 2025. Verfasst von Marta Laganà und 12 weiteren Autor:innen. Hauptthemen laut MEDLINE: Neuroendocrine Tumors, Pancreatic Neoplasms, Intestinal Neoplasms, Stomach Neoplasms. Die Arbeit nennt 38 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Neuroendocrine neoplasms (NENs) are rare tumors with increasing incidence. Data on the prognosis of NEN patients in the real-world setting are limited. We aim to explore survival predictors and the impact of novel treatments in a cohort of patients with NENs from various primary sites. This was a retrospective study of subjects diagnosed with gastroenteropancreatic (GEP) or thoracic NENs and referred to a single institution over more than a decade (2010–2023). The primary objective was to describe the overall survival (OS) and progression-free survival (PFS) of patients with advanced-stage disease undergoing first, second, and third-line therapy. The secondary objectives were to identify predictors of OS and PFS. We included 239 NEN patients. Systemic antineoplastic therapies were administered to 149 subjects (62.3%). In patients treated only with first-line therapy, the OS rate was 75 and 74% at 12 and 18 months, respectively. We observed significant univariable associations between Ki-67 index, primary tumor site, morphology, clinical stage, and OS. The multivariable analysis confirmed a significant association between Ki-67 index, clinical stage, and OS. In patients undergoing second-line therapy, the OS rate was 72 and 61% at 12 and 18 months, respectively, and the Ki-67 index was again associated with OS in the multivariable analysis. GEP NEN patients who received 177 Lu-Dotatate showed a numerically higher OS rate at 24 months compared to those who did not receive radioligand therapy. In this real-world study of patients with NENs, we confirmed Ki-67 as a strong prognostic parameter and suggested that 177 Lu-Dotatate has the potential to prolong OS.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neuroendocrine TumorsPancreatic NeoplasmsIntestinal NeoplasmsStomach NeoplasmsHumansRetrospective StudiesFemaleMaleMiddle AgedAgedPrognosisAdultAged, 80 and overSurvival Rate

Stichwörter der Autor:innen

Ki-67neuroendocrine neoplasmsprognosisradioligand therapy

Autor:innen und Institutionen

ORCID-Profile: Vito Amoroso

Zitieren

APA

Laganà, M., Gallo, F., Salvetti, M., Smussi, D., Esposito, A., Carola, G., Carpani, M., Morocutti, F., Cosentini, D., Pedersini, R., Grisanti, S., Berruti, A., & Amoroso, V. (2025). Predictors of survival outcomes in patients with neuroendocrine neoplasms: a real-world retrospective study. Endocrine-Related Cancer. https://doi.org/10.1530/erc-25-0243

Vancouver

Laganà M, Gallo F, Salvetti M, Smussi D, Esposito A, Carola G, et al. Predictors of survival outcomes in patients with neuroendocrine neoplasms: a real-world retrospective study. Endocrine-Related Cancer. 2025. doi:10.1530/erc-25-0243

BibTeX
@article{Lagan2025,
  author = {Laganà, Marta and Gallo, Fabio and Salvetti, Maddalena and Smussi, Davide and Esposito, Andrea and Carola, Giorgia and Carpani, Matteo and Morocutti, Filippo and Cosentini, Deborah and Pedersini, Rebecca and Grisanti, Salvatore and Berruti, Alfredo and Amoroso, Vito},
  title = {Predictors of survival outcomes in patients with neuroendocrine neoplasms: a real-world retrospective study},
  journal = {Endocrine-Related Cancer},
  year = {2025},
  doi = {10.1530/erc-25-0243}
}
Kostenlos starten →